Name: Paritaprevir

---

Type: small molecule

---

Groups: approved

---

Indication: For use in combination with ombitasvir, ritonavir and dasabuvir for the treatment of HCV genotype 1, and with ombitasvir and ritonavir for the treatment of HCV genotype 4.

---

Accession Number: DB09297 ( DB09297)

---

Description: Paritaprevir is an acylsulfonamide inhibitor of the NS3-4A serine protease manufactured by Abbott Laboratories that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1. Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3.

---

Structure:

---

Prescription Products:

Name	Dosage	Strength	Route	Marketing Start	Marketing End	Country
Holkira Pak	kit; tablet	Array	oral	06-01-2015		Canada
Technivie	kit	Array	Array	24-07-2015		US
Technivie	tablet	Array	oral	24-11-2015		Canada
Viekira Pak	kit	Array	Array	19-12-2014		US

---

Generic Prescription Products: Not Available

---

Over the Counter Products: Not Available

---

International Brands

• No Brands

---

Brand Names

• No Brands

---

Brand Mixtures

Brand Name	Ingredients
Technivie	Ombitasvir + Paritaprevir + Ritonavir
Viekira Pak	Dasabuvir + Ombitasvir + Paritaprevir + Ritonavir
Holkira Pak	Ombitasvir + Dasabuvir + Paritaprevir + Ritonavir
Technivie	Ombitasvir + Paritaprevir + Ritonavir

Brand Name	Ingredients
Technivie	Ombitasvir + Paritaprevir + Ritonavir
Viekira Pak	Dasabuvir + Ombitasvir + Paritaprevir + Ritonavir
Holkira Pak	Ombitasvir + Dasabuvir + Paritaprevir + Ritonavir
Technivie	Ombitasvir + Paritaprevir + Ritonavir

---

Categories

• No Category

Indication: For use in combination with ombitasvir, ritonavir and dasabuvir for the treatment of HCV genotype 1, and with ombitasvir and ritonavir for the treatment of HCV genotype 4.

---

Pharmacodynamics: Not Available

---

Mechanism of action: Not Available

---

Absorption: Not Available

---

Volume of distribution: Not Available

---

Protein binding: Not Available

---

Metabolism: Not Available

---

Route of elimination: Not Available

---

Half life: Not Available

---

Clearance: Not Available

---

Toxicity: Not Available

---

Affected organisms

• Not Available

---

SNP Mediated Adverse Drug Reactions

• Not Available

Manufacturers:

• Not Available

---

Packagers:

• Not Available

---

Dosage forms

Form	Route	Strength
Kit; tablet	oral
Kit
Tablet	oral

Form	Route	Strength
Kit; tablet	oral
Kit
Tablet	oral

---

Prices

Unit description	Cost	Unit

Unit description	Cost	Unit

---

Patents

Country	Patent Number	Approved	Expires (estimated)

Drug Interactions

Drug	Interaction

Drug	Interaction

---

Food Interactions:

• Not Available

Kingdom: Not Available

---

Super Class: Not Available

---

Class: Not Available

---

Sub Class: Not Available

---

Direct Parent: Not Available

---

Alternative Parents:

• Not Available

---

substituent:

• Not Available

Synthesis Reference: Not Available

---

General Reference: Not Available

---

External Links:

Resource	Link

Resource	Link

---

ATC Codes:

• Not Available

---

AHFS Codes:

• Not Available

---

MSDS: Download